A drug that will be used to treat patients with obsessive-compulsive disorder (OCD) has been invented by artificial intelligence (AI), and it will be used in human trials in a world first for machine learning in medicine. Created by British star-up, Exscientia, and Japanese pharmaceutical firm, Sumitomo Dainippon Pharma, the AI drug only took 12 months to develop, compared to typical drug development that takes about five years to get to trial. Prof Andrew Hopkins, the chief executive of Exscienta, told BBC, “We have seen AI for diagnosing patients and for analyzing patient data and scans, but this is a direct use of AI in the creation of a new medicine.”
Created by using algorithms that filtered through potential compounds in a huge database of parameters, the drug molecule is known as DSP-1181. The first phase of the trial will be in Japan, and if it is successful, there will be more global tests. Potential drugs for cancer and cardiovascular disease treatments are already in the works for the firm. They hope to have another molecule ready for clinical trials by the end of this year.